EGFR and non-small cell lung carcinoma: Therefore, we conducted this pilot study to assess the safety, pharmacokinetic (PK) profile as well as therapeutic efficacy of apatinib plus gefitinib in non‐squamous EGFR‐mutant NSCLC patients.